Navigation Links
Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
Date:5/4/2012

including ADHD, major depressive disorder, and negative symptoms of schizophrenia."

Vyvanse is a prescription medicine currently approved in the United States and Canada, as well as in Brazil under the name Venvanse, for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). Vyvanse should be used to treat only ADHD.

Vyvanse is a Schedule II controlled substance. Stimulants, such as amphetamines and methylphenidates, are subject to misuse, abuse, addiction, and criminal diversion. Misuse of amphetamines may cause sudden death and serious cardiovascular adverse events.

INTUNIV is indicated for the treatment of ADHD as monotherapy and as adjunctive therapy to stimulant medications in children and adolescents ages 6 to 17. The effectiveness of INTUNIV for more than 9 weeks has not been systematically evaluated. The physician electing to use INTUNIV for extended periods should periodically reevaluate its long-term usefulness for the individual patient.

Patients with a history of hypersensitivity to INTUNIV, its inactive ingredients, or other products containing guanfacine (eg, TENEX®) should not take INTUNIV.

Both Vyvanse and INTUNIV are indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).

Highlights of the scientific presentations are noted below. Information about scientific presentations mentioned in this release is embargoed until the respective presentation sessions have taken place at the meeting.

ADHD Presentations

Lisdexamfetamine Dimesylate

  • May 5, 2012; 11:00 am to 12:30 pm EDT
    Duration of Action of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
    Scientific and Clinical Report #2 (Oral Presentation) - Location: 109B, Level 1
  • May 6, 2012; 1:00 pm to 3:00 pm EDT
    Effect of Li
    '/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... According to a new market ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... of 10.1% from 2014 to 2020. Biological ... used in the treatment and prevention of various diseases ... medical disorders. Biological drugs include therapeutic proteins, monoclonal antibody ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 /PRNewswire-iReach/ -- ... just recognized as one of the fastest growing ... past few years, the company has undergone significant ... research, late phase global clinical development, anti-viral and ... 2 years, WCCT Global has successfully participated in ...
(Date:9/1/2014)... 1, 2014 Research and Markets ... Minimally-Invasive Biomarkers in Alzheimer,s Disease: A Comprehensive Analysis and ... report to their offering. This report ... developments relating to early-stage minimally-invasive biomarkers in Alzheimer,s disease, ... and candidates in the AD drug pipeline, and applicable ...
Breaking Medicine Technology:CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 2CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 3CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 4CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 5CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 6Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014 2
... ANX ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the proposed proprietary name "Exelbine™" for the Company,s product candidate ANX-530 (vinorelbine injectable emulsion). , ... , ... ... ...
... Ardea Biosciences, Inc. (Nasdaq: RDEA ) a biotechnology company focused on the development of small-molecule ... fourth quarter and full-year 2009 financial results and provided key upcoming clinical development milestones and financial guidance ... ... , ...
Cached Medicine Technology:ADVENTRX Receives Brand Name Acceptance for ANX-530 2ADVENTRX Receives Brand Name Acceptance for ANX-530 3ADVENTRX Receives Brand Name Acceptance for ANX-530 4Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 2Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 3Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 4Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 5Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 6Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 7Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 8Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 9Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 10Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 11
(Date:9/2/2014)... Recently, Os-Monitor.com, an innovative company that provides many ... of employee internet monitoring products ( http://www.os-monitor.com ). Furthermore, ... to 10% off, on these useful items. , ... 20 different kinds of high end monitoring programs on ... companies of all sizes. With its high end programs, ...
(Date:9/2/2014)... A simple awareness campaign in general practice identifies new ... at ESC Congress today by Professor Jean-Marc Davy from ... the most common cardiac arrhythmia. It multiplies the risk ... of stroke risk by five-fold. Similarly, AF is responsible ... AF is often overlooked and diagnosed too late. In ...
(Date:9/2/2014)... Developers and plugin specialist of Final Cut ... from Pixel Film Studios. , “ProIntro has enabled users ... Christina Austin, CEO of Pixel Film Studios. “Blurring the ... game changer.” , Learn how to create a title ... Studios. ProIntro is a package of professionally designed titles ...
(Date:9/2/2014)... FL (PRWEB) September 02, 2014 ... for about a decade, primarily to help people ... time, there are three developed systems,” says Dana ... approaches substantively differ, the goals are much the ... support of some type of harmonica.” , The ...
(Date:9/2/2014)... AURO the enterprise Canadian Public ... expansion of its leadership team with the appointment of ... Liang joins AURO in conjunction with his current role ... with the operations, product management and engineering teams to ... well as ensuring effective internal and external controls are ...
Breaking Medicine News(10 mins):Health News:Useful Employee Internet Monitoring Products Now For Sale At Os-Monitor.com 2Health News:Simple awareness campaign in general practice identifies new cases of AF 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 3Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 2Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 3
... new study finds that, despite efforts in the last ... significantly less likely than white patients to receive therapy ... study conclude that efforts to close treatment gaps initiated ... The report appears in the February 15, 2008 issue ...
... Conn., Jan. 6 Therap Services, the leading,provider ... has announced the promotion of Allison Dudo to ... responsibility of,providing help and technical guidance to users ... key part of our success, and we were ...
... heavily than male peers, field study finds , , SUNDAY, ... of college drinking behavior shows that parties with drinking ... parties encourage college women to drink more heavily than ... drinking have relied largely on individual behavior and self-reports ...
... Year,s,resolution is to lose weight, calcium and dairy can help, ... Science Hawley,Almstedt and her student Alexandra Hybki. The everyday nutrients ... down this year., People on fad diets or extreme ... foods are high in fat. Some dieters go,so far as ...
... Holdings, Inc. President Robert Oswald provides a shareholder,update., ... as we opened 5 new,locations across Canada, including the ... were fortunate to have our Official Spokesperson,for Canada, Mr. ... opening,events for our new locations. I was very pleased ...
... radiation after early-stage disease is removed, researchers say , FRIDAY, ... have not yet spread contain cells with a predisposition to ... just because a cancer has not yet spread doesn,t mean ... warned researchers at the Salk Institute for Biological Studies in ...
Cached Medicine News:Health News:Racial disparities persist in cancer care 2Health News:Therap Services Promotes Allison Dudo to Assistant Director of Training 2Health News:College Drinking Games Lead to Higher Blood Alcohol Levels 2Health News:Milk Does a Body and a Waistline Good 2Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 2Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 3Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 4Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 5Health News:Localized Breast Cancer Cells Have Potential to Spread 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: